AAV KCNQ4 Gene Delivery for Inner Ear Hearing Loss
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for KCNQ4-associated hearing loss are inadequate, and there is a need for effective methods to address this condition.
Innovation Solution
The use of AAV particles, such as rAAV Anc80-KCNQ4 or rAAV Anc80-KCNQ4-Inhibitory-RNA, to deliver KCNQ4 gene products or inhibitory nucleic acids to inner ear cells, utilizing specific promoters and AAV inverted terminal repeats to enhance gene expression or inhibition, thereby treating hearing loss.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for KCNQ4-associated hearing loss, then treatment is available, but treatment effectiveness is inadequate
Solution Approach 1:
The patent uses AAV (adeno-associated virus) particles as an intermediary delivery vehicle to transport the KCNQ4 gene or inhibitory nucleic acids into inner ear cells. This viral vector serves as a mediator that overcomes the inadequacy of current treatments by providing a reliable mechanism for gene delivery, thereby improving treatment effectiveness while maintaining feasibility through established viral vector technology
Solution Approach 2:
The patent replaces conventional mechanical or chemical treatment methods with a biological gene delivery system. Instead of using traditional pharmaceuticals or surgical interventions, the invention employs genetic modification through AAV-mediated delivery of functional KCNQ4 genes or inhibitory RNAs, achieving more effective treatment of KCNQ4-associated hearing loss
2Reliability
If AAV particles are used to deliver KCNQ4 gene products, then hearing function improves, but delivery complexity increases
Solution Approach 1:
The patent divides the delivery system into distinct functional components: the AAV particle structure (with capsid proteins), the genetic payload (KCNQ4 gene or inhibitory nucleic acid), and the target cell (inner ear cell). This segmentation allows each component to be optimized independently - the capsid for efficient delivery, the payload for functional effect, and the target for specificity - thereby achieving reliable hearing function improvement while managing complexity through modular design
Solution Approach 2:
The patent employs different AAV capsid serotypes (such as AAV2, AAV5, AAV8, AAV9) with varying properties to optimize delivery to different tissues. By changing the capsid parameters while maintaining the overall AAV particle structure, the system achieves efficient gene delivery to inner ear cells without requiring complete redesign of the entire delivery system, thus improving hearing function while controlling complexity
3Reliability
If KCNQ4 variants are inhibited, then hearing loss is treated, but specificity requirements increase
Solution Approach 1:
The patent employs tissue-specific promoters (such as those driven by hair cell-specific or cochlear-specific regulatory elements) to ensure that the KCNQ4 gene or inhibitory nucleic acids are expressed only in the desired inner ear tissues. This localizes the genetic effect to specific cell types and regions, achieving effective hearing loss treatment while maintaining high specificity and avoiding off-target effects in other tissues
Solution Approach 2:
Instead of attempting to correct mutant KCNQ4 genes through complex gene editing approaches, the patent takes an inverse approach by using AAV particles to deliver functional wild-type KCNQ4 genes or inhibitory RNAs that specifically target and suppress KCNQ4 variants. This inversion of the problem-solving approach simplifies the specificity requirement by directly inhibiting the harmful variant rather than attempting precise correction of the mutant sequence
Data Source
AI summary
The present disclosure provides technologies comprising a polynucleotide capable of expressing and/or inhibiting a KCNQ4 gene product.